Invesco Ltd. Acquires 18,871 Shares of Elanco Animal Health Incorporated $ELAN

Key Points

• Invesco Ltd. increased its stake in Elanco Animal Health by 3.5%, owning 555,262 shares worth approximately $5.83 million as of the end of the most recent quarter.
• Several institutional investors significantly boosted their positions in Elanco Animal Health, with Mariner LLC and First Trust Advisors LP increasing their stakes by 79.6% and 508.2%, respectively, during the fourth quarter.
• Elanco Animal Health's stock recently received upgrades from analysts, with ratings reflecting a strong outlook; the average target price for the stock is currently $17.33.

Invesco Ltd. raised its holdings in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 3.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 555,262 shares of the company's stock after acquiring an additional 18,871 shares during the period. Invesco Ltd. owned about 0.11% of Elanco Animal Health worth $5,830,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Allworth Financial LP lifted its holdings in shares of Elanco Animal Health by 791.7% in the first quarter. Allworth Financial LP now owns 2,354 shares of the company's stock valued at $25,000 after purchasing an additional 2,090 shares in the last quarter. CoreCap Advisors LLC acquired a new position in shares of Elanco Animal Health in the fourth quarter valued at approximately $29,000. NBC Securities Inc. acquired a new position in shares of Elanco Animal Health in the first quarter valued at approximately $40,000. Parallel Advisors LLC grew its position in Elanco Animal Health by 92.2% during the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock worth $41,000 after buying an additional 1,852 shares in the last quarter. Finally, Versant Capital Management Inc grew its position in Elanco Animal Health by 65.9% during the first quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock worth $46,000 after buying an additional 1,740 shares in the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

Elanco Animal Health Trading Down 0.4%

Shares of ELAN stock traded down $0.08 during mid-day trading on Friday, hitting $18.38. The company's stock had a trading volume of 71,268,743 shares, compared to its average volume of 7,713,274. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.40 and a current ratio of 2.60. The company's fifty day simple moving average is $15.55 and its 200-day simple moving average is $12.69. The company has a market cap of $9.13 billion, a PE ratio of 21.37, a P/E/G ratio of 3.42 and a beta of 1.66. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $18.87.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.20 by $0.06. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The firm's revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period last year, the business posted $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, equities research analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ELAN has been the topic of a number of analyst reports. William Blair raised Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday, June 26th. Leerink Partnrs upgraded Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 17th. UBS Group upped their target price on Elanco Animal Health from $18.00 to $19.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. Leerink Partners upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 target price for the company in a research note on Thursday, July 17th. Finally, Zacks Research cut Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $17.33.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.